Siegfried and BASF reflect on recent API deal

By Gareth Macdonald contact

- Last updated on GMT

Siegfried and BASF reflect on recent API deal
Selling most of its API business had only a limited impact on revenues in 2015 according to BASF, which has reiterated its plan to retain its ibuprofen, PEG and omega-3 operations.

BASF published its 2015 results on February 26, revealing that revenue generated by its nutiriton and health division – part of its performance products segment – was €1.99bn ($2.18bn), down €31m year-on-year.

The firm attirbuted the decline to competition in the vitamin E and aroma chemicals markets and also to the sale of several APIs – including ephedrine, pseudoephedrine and caffeine - and its custom synthesis operations to Siegfried Holding last year.

At the time BASF said the sell off – which included facilities in Vinden, Germany, Evionnaz Switzerland and Saint-Vulbas, France - would let it focus on the most lucrative ingredients in its portfolio, namley ibuprofen, polyethylenglycol (PEG) and omega-3.

Spokesman Andres Christian Orthofer confirmed this is still the plan, telling us the APIs will “remain a core focus in BASF’s portfolio​.”

Siegfried plans

Siegfried spokesman Peter Gehler told us his firm is already using the acquired APIs to expand its customer base.

As we have already access to 70% of our target customer portfolio our main focus is to expand business and elaborate synergies based on our combined expanded asset network and our additional drug product segments.”

The Swiss firm – which is due to publish its full year results this month – still uses BASF as a distributor for the drug actives, although this agreement will soon come to an end.

Gehler told us Siegfried will take over distribution in the second half of the year, adding that: “From then on we will take over all their [BASF's] customers.”

He also confirmed that Siegfried has retrained all of BASF’s former custom synthesis clients.

Related news

Show more

Related products

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Follow us


View more